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ABSTRACT
Calf thymus DNA polymerase alpha (pol a) and
bacteriophage T4 DNA polymerase (pol T4) were
exploited as model enzymes to investigate the
molecular mechanism of inhibitory action of N2-(p-n-
butylphenyl)dGTP (BuPdGTP) and 2-(p-n-butyl-
anilino)dATP (BuAdATP) on the BuPdNTP-susceptible
alpha polymerase family. Kinetic analysis of inhibition
of pol a with mixtures of complementary and non-
complementary template:primers indicated that both
nucleotides induced the formation of a polymerase:
inhibitor:primer-template complex. Primer extension
experiments using the guanine form as the model
analog indicated that pol a cannot utilize these
nucleotides to extend primer termini. In contrast, pol
T4 polymerized BuPdGTP, indicating that resistance to
polymerization is not a common feature of the inhibitor
mechanism among the broad membership of the alpha
polymerase family.
INTRODUCTION
The dNTP analogs, N2-(p-n-butylphenyl)dGTP (BuPdGTP), and
2-(p-n-butylanilino)dATP (BuAdATP), are potent and highly
selective inhibitors of mammalian pol a and several other
replication-specific polymerases of the pol a type (1-4). These
BuPdNTPs have found wide use as pol a-specific inhibitor-probes
and as tools for distinguishing enzymes of the pol a family from
other mammalian DNA polymerases, including the aphidicolin-
sensitive DNA polymerases, delta and epsilon (5).
To enhance the utility of the BuPdNTPs as probes of the
structure of pol a and its dNTP-binding site, we seek to
characterize precisely the molecular mechanism of the BuPdNTP-
pol a interaction. Specifically, we aim to determine the extent
to which the mechanism of these nucleotides mimics that of their
pol a-specific base forms, N2-(butylphenyl)guanine (BuPG) and
2-(butylanilino)adenine (BuAA; ref. 6), and that of 6-(p-
hydroxyphenyl-hydrazino)uracil (H2 HPUra), the prototypic,
pol HI-specific dGTP analog on which the design of this inhibitor
class was originally based (7). In this paper, we address three
fundamental questions with respect to the BuPdNTP-pol a
interaction: (1) Do the BuPdNTPs induce the sequestration of
pol a into a catalytically inactive DNA:inhibitor:protein complex?
(2) Does the action of the BuPdNTP form on pol at involve
polymerization of its dNMP moiety to the primer-terminus? (3)
Does the basic mechanism discerned for mammalian pol ca apply
more broadly across the alpha-like family of BuPdNTP-sensitive
DNA polymerases which display strong primary sequence
homology with the mammalian enzyme?
MATERIALS AND METHODS
Nucleotides
Homopolymers and unlabeled forms of dATP, dCTP, dGTP,
and dTTP were purchased from Pharmacia. BuAdATP and
BuPdGTP were synthesized and purified as described in,
respectively, (2) and (8).
Source and assay of DNA polymerases
Calf thymus DNA pol a was purified on an immunoaffinity
matrix prepared from protein A-Sepharose 4B (Pharmacia) and
an anti-calf thymus pol ca monoclonal antibody provided by Dr.
Lucy Chang (hybridoma 17; ref. 9). The immunoaffinity matrix
was prepared and used to purify enzyme as described (9). Sodium
dodecylsulfate-polyacrylamide gel (SDS-PAG) electrophoretic
analysis and analysis of the polymerase activity of the
immunopurified polymerase indicated a four peptide structure
and a specific activity essentially identical to that described in
(9). Pol a activity was assayed in the presence of activated calf
thymus DNA or synthetic homopolymers as described in (1).
Poly(dA):oligo(dT)12_18 and poly(dC):oligo(dG)12_18 were
prepared by annealing homopolymer and oligomer in the ratio
of 10 A260 units of polymer: 0.5 A260 units of oligomer.
Bacteriophage T4 DNA polmerase (pol T4) was an homogeneous
* To whom correspondence should be addressed
.=) 1991 Oxford University Press
1628 Nucleic Acids Research, Vol. 19, No. 7
preparation of recombinant enzyme prepared and assayed as
described in ref. 15 and kindly provided by Dr. Linda Reha-
Krantz.
Assay of primer extension
Primer extension was assessed by autoradiographic analysis of
denaturing DNA sequencing gel electropherograms of the
products resulting from the action of pol a on a 5'[32P]-labeled
17 residue oligonucleotide primer annealed to a 29 residue
template. The structure of the primer (M13 sequencing primer
# 1211, Boehringer Mannheim) and template (Operon) is shown
in the top panel of Fig. 1. The labeling of primer was based on
the method described in (10); 0.125 OD26 U of primer was
incubated with 500 lzCi of [Ly32P]-ATP (3000Ci/mmol) and 5
units of polynucleotide kinase (New England Biolabs) at 35°C
for 60 min in 50 Al of labeling buffer, (50 mM Tris * HCl (pH
7.6), 10 mM MgCl2, 5 mM dithiothreitol, and 1 mM
spermidine). The latter mixture was heated at 1000 for 2 min
and desalted on a 250 Al Sephadex G-25 column equilibrated with
50 mM Tris * HCl (pH 7.6). The desalted primer was mixed with
an equal amount of the 29 residue template in labeling buffer
minus spermidine, and the solution was incubated at 50°C for
5 min; to complete annealing, the solution was held at room
temperature for 60 min and then quenched in ice.
The reaction conditions for primer extension by pol ax and pol
T4 were adapted from those described for assay of pol a in ( 11);
0.1-0.2 units of enzyme were incubated in the presence/absence
of dGTP or BuPdGTP at 350 for 30 min in 12.5 1.l of a solution
containing 20 mM potassium phosphate buffer (pH 7.5), 8 mM
MgCl2, 4 mM dithiothreitol, 0.1 mM EDTA, and 50 itg/ml of
labeled template:primer. The reaction was terminated by addition
of 4 ,^l of stop buffer (95 % formamide, 20 mM EDTA, 0.05%
bromophenol blue, and 0.05% Xylene cyanol FF), and the
mixture was boiled for 2 min and placed on ice. A 5 pil sample
of the quenched mixture was applied to a 12% polyacrylamide
DNA sequencing gel and electrophoresed for 4 hr at 1500 volts
at constant power. The gel was dried and exposed to a 14" x 17"
sheet of Fuji RX type X-ray film for 1-6 hr and developed.
Calf thymus terminal deoxyribonucleotidyl transferase (TdT;
New England Nuclear) was used to obtain a sequencing ladder
for identifying the length of specific products of primer extension
with BuPdGTP; 0.25 units of TdT were incubated at 37°C with
1 ,Lg of [32P]-labeled primer in the presence of 50 AtM BuPdGTP
in 10 of a TdT assay buffer described in (12). After 30 min
the incubation mixtures were quenched with stop buffer and
subjected to gel analysis as described above for the products of
pol a-catalyzed primer extension.
RESULTS
Kinetic analysis of inhibitor action
Table I summarizes relevant features of the interaction of
immunopurified calf thymus pol a and the natural and
N2-substituted dNTPs (BuPdNTPs). In the presence of activated
DNA the enzyme displayed a Km of approximately 8 AM for the
natural purine dNTPs and Kis for the BuPdNTPs in the
nanomolar range. In contrast to human (HeLa cell) and Chinese
hamster ovary cell pol alphas, both of which display essentially
equal sensitivity to BuPdGTP and BuAdATP (1,2), the calf
enzyme consistently displayed a sensitivity to BuPdGTP 3-4
times that which it displayed to BuAdATP. Differences in potency
notwithstanding, the inhibitory effect of each BuPdNTP in the
presence of activated DNA was, as expected, subject to
competition with the analogous purine dNTP. The action of
BuAdATP was not subject to detectable competition by dGTP,
dCTP or dTTP, nor was the action of BuPdGTP antagonized
detectably by dATP, dCTP, or dTTP.
The BuPdNTPs also were inhibitory in the presence of
homopolymeric template:primers; the action of each inhibitor was
subject to competition by the specific dNTP serving as the
nucleotide substrate, and the potency of each was significantly
influenced by its complementarity to the template. Two template
primers were used, poly (dC):oligo(dG) and poly (dA):oligo(dT);
unfortunately, the use of the BuAdATP-complementary template,
poly(dT), was not possible, because it was not sufficiently
effective in promoting oligo(dA)-driven synthesis. The
Table I. Calf Thymus Pol a vs Inhibitory and Natural dNTPs
Nucleotide(a)
Condition or Property BuPdGTP BuAdATP dTTP dCTP dGTP dATP
+DNA(b) 0.002lzM 0.008AM N.A.(c) N.A. 8auM 8,aM
Inhibitory action with dGTP dATP N.A. N.A. N.A. N.A.
DNA competively only only
antagonized by:
+poly(dC):oligo(dG)(d) 0.002jiM 1.9/M N.A. N.A. lOAM N.A.
Inhibitory action with dGTP dGTP N.A. N.A. N.A. N.A.
poly(dC):oligo(dG) only only
competitively antagonized
by:
+poly(dA):oligo(dT)(d) 0.04AM O.5uM IOM N.A. N.A. N.A.
Inhibitory action with dTTP dTTP N.A. N.A. N.A. N.A.
poly(dA):oligo(dT) only only
competitively antagonized
by:
(a)KM or Kj; the value represents an average of three determinations with a S.D. of + 20%.(b)Assayed in the presence of activated DNA as described in the methods section.()N.A., not applicable.(d)Assayed in the absence of activated DNA and in the presence of synthetic template:primer
as described in the methods section.
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poly(dC):oligo(dG)-dependent reaction displayed a Km of 10 yM
for dGTP and a Ki of 0.002 ltM for BuPdGTP; both values
closely approximated those determined with activated DNA. The
poly(dC):oligo(dG)-driven reaction was, as expected, relatively
resistant to the non-complementary BuAdATP; the latter
displayed a Ki of 1.9 t4M, a value nearly 250 times that
observed with natural DNA as template primer. The
poly(dA):oligo(dT)-driven reaction, in which the template was
not complementary to either BuPdNTP, displayed resistance to
both inhibitors relative to that displayed with activated DNA.
The relative susceptibility of the enzyme to the guanine analog
noted in the presence of activated DNA was even greater in the
presence of the noncomplementary poly(dA) template; the Ki for
BuPdGTP increased roughly 20-fold (0.002 ttM to 0.04 /M)
while that for BuAdATP increased approximately 60-fold (0.008
,^M to 0.5 EM).
BuPdNTP action on pol a does not involve polymerization
of the dNMP moiety to the primer terminus
In contrast to their base and lower nucleotide forms, the
BuPdNTPs have the potential to serve as substrates for
polymerization by the target enzyme. To assess the potential of
the BuPdNTPs for incorporation by pol ca, we exploited
BuPdGTP as the model inhibitor and used sequencing gel analysis
to assess its capacity to extend the 17 residue oligonucleotide
primer shown in the upper panel of Figure 1. Specifically, we
compared the capacity of dGTP and BuPdGTP to extend the
primer by one nucleotide residue. The results are shown in the
pol ax middle panel of Fig. 1. The template:primer served as an
effective DNA substrate. In the presence of a complete mixture
of natural dNTPs, the bulk of the primer was extended to its full,
29 residue length (lane L). In the presence of dGTP at
approximately 5, 10, and 20 times its Kn, the enzyme extended
the primer by 1 residue (lanes D-F), as expected from the
template structure. However, in the presence of BuPdGTP at
approximately 50, 500 and 5000 times its Ki (lanes H, I, and
J, respectively) no primer extension was detected, even upon
prolonged autoradiographic exposure of the film.
Given a complementary template, BuPdNTPs act by
sequestering pol a to template:primer
Paradigm for sequestration mechanism. The design of the
butylphenyl purines and their respective dNTP forms (1,2) was
based on the structure of an arylpurine prototype which we had
found to be a selective inhibitor of bacterial DNA pol HI (6,7).
The pol HI-specific prototype acts specifically by sequestering
the target enzyme to template:primer (13,14). The mechanism
of sequestration and the structural features essential to it are
defined schematically in Fig. 2. As shown in the left panel, the
inhibitor molecule has two essential domains, an aryl domain
which binds the dNTP binding site of its target enzyme and a
base pairing domain comprised of 3 substituents that hydrogen
bond with the appropriate pyrimidine (cf., specific base pairs in
the middle panel). Induction of complex formation by the inhibitor
(cf. scheme in right panel) requires a template:primer with a base-
paired 3' OH primer terminus, and, just distal to this terminus,
an unapposed template pyrimidine complementary to the base-
pairing domain of the inhibitor. Given the template:primer
structure, the inhibitor substitutes for the appropriate incoming
purine dNTP and anchors the template pyrimidine to the active
site of the enzyme, sequestering the latter in a catalytically inactive
complex.
Analysis ofcomplexformation. The results ofthe primer extension
experiments (Fig. 1) and the results of the kinetic analysis of
BuPdNTP action (Table I) were consistent with the conventional
sequestration mechanism of inhibitor-induced complex formation.
To determine specifically whether the latter mechanism actually
Figure 1. Sequencing gel analysis of primer extension in the presence of dGTP
and BuPdGTP. Upper panel, structure of the template:primer. Middle panel,
autoradiographic analysis of the products of pol ca action on the above
primer:template. 5 [32p] labeling of the primer and the preparation and processing
of the incubation mixtures are described in the methods section. Lane A,
template:primer, no enzyme; Lanes B and G, template:primer plus enzyme, no
dNTP; lanes D, E, and F:dGTP at, respectively, 50, 100, and 200 yM; lanes
H, I, and J: template:primer plus enzyme with BuPdGTP at, respectively, 0.1,
1.0, and 10 1tM. Lane C:dGTP, dCTP, dATP, and dTTP at 50 jtM each; lane
L, primer after treatment with TdT in the presence of 50 ltM BuPdGTP; lane
K, primer plus TdT treatment in the absence of BuPdGTP. Conditions for TdT
treatment are described in the Methods section. Lower panel: Products of pol
T4 action on the above template:primer. Lane A, template:primer, no enzyme;
lane E, template:primer plus enzyme plus 25 ItM dGTP; lane F, template:primer
plus dATP, dGTP, dCTP, and dTTP at 25 mM each; lanes B, C, and
D:template:primer plus BuPdGTP at, respectively, 10, 100 and 1000 nanomolar.
Prmer (17mcr)-_
5'*GTAAAACGACGGCCAGT
3' CATTTT GCTGCCGGTCACATGCCGATCCC5'
Template (29mer)
A B C D E F G H J K L
.W
A
4T lb * 4
*4* * 4
~~~~~~~~lb 1"~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
A B C D E F
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Figure 2. Structure and mechanism of the simple N2-arylpurine prototype. Left panel: Structure, showing base pairing domain and aryl domain. Middle panel: Base
pairs between cytosine and a N2-(aryl)guanine Qower section) and thymine and a 2-anilinoadenine (upper section). Right panel: Schematic representation of the
mechanism of inhibitor-induced sequestration of its target enzyme to template:primer.
Table II. Demonstration of BuPdNTP-Induced Sequestration of Pol ca
Incubation conditions(a) pmol dTMP polymerized
Control +BuPdGTP +BuAdATP
(0.0251A) (0. IIM)
i) + poly(dA):oligo(dT) only
ii) - poly(dA):oligo(dT) + activated DNA(b)
iii) + poly(dA):oligo(dT) + activated DNA(b)
iv) + poly(dA):oligo(dT) + activated DNA(b) + 800
,tM dGTP
v) + poly(dA):oligo(dT) + activated DNA(b) + 800
,tM dATP
vi) + poly(dA):oligo(dT) +
poly(dC):oligo(dG)kc)
vii) + poly(dA):oligo(dT) +
poly(dC):oligo(dG) + 800 iuM dGTP
viii) + poly(dA):oligo(dT) + poly(dC)(e)
ix) + poly(dA):oligo(dT) + oligo(dG)(0
63 59 61
<1 <1 <1
58 5.3 5.2
61 60 5.8
62 5.4 63
60 5.8 N.D.(d)
61 60 N.D
61 62 N.D.
62 60 N.D.
(a)assay conditions were those described in the methods section
(b)activated DNA was present at 0.010 mg/ml, a concentration 200 times less than that used in
conventional, DNA-directed enzyme assay
(C)present at a concentration of 0.002 ug/m1
(d)not determined
)poly(dC) was present at a concentration equivalent to that present as poly(dC):oligo(dG) in (c)
t0oligo(dG) was present at a concentration equivalent to that present as poly(dC):oligo(dG)in (c)
obtained, we used an approach applied to demonstrate
sequestration of bacterial pol mI by the pol HI-specific inhibitor
H2 HPUra (13,14). The approach exploits the assay of
polymerase activity, and it depends on the relatively high level
of resistance of pol a to BuPdNTPs when synthesis is driven
by a template which is not complementary to the base-pairing
domain of the inhibitor, (i.e. a template which cannot significandy
support formation of an inhibitor:DNA:enzyme complex).
The approach exploits two different template:primers: a non-
complementary homopolymer:oligomer on which incorporation
of a radiolabelled dNMP is followed, and a sequestration-specific
template:primer which provides an inhibitor-complementary
pyrimidine in its template and the specific primer terminus
structure required for inhibitor-induced sequestration (cf., Fig.
2, right panel). Specifically, oligo(dT) synthesis on poly(dA) is
followed in the presence of a subsaturating concentration of the
AMT
a
domain
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polymerase and a concentration of inhibitor which: (i) generates
little, if any, inhibition of dTMP incorporation and (ii) exceeds
the lower Ki applicable in the presence of inhibitor-
'complementary' natural DNA. The natural DNA is added at a
concentration insufficient to support significant detectable dTMP
incorporation per se but sufficient to serve as a trap tor the bulk
of the enzyme present. If the BuPdNTP induces sequestration
of pol a on the natural DNA, it effectively pulls the enzyme away
from the (dA):(dT) template:primer, and dTMP incorporation
into oligo(dT) is reduced accordingly. Table II summarizes the
results of applying this method to assess the capacity of BuAdATP
and BuPdGTP to induce sequestration of pol a.
At a concentration approximately 12 times its Ki on
complementary natural DNA, neither BuPdGTP nor BuAdATP
significantly inhibited poly(dA)-driven oligo(dT) synthesis (row
i). However, in the presence of a low concentration of
complementary, activated DNA (a concentration which did not
itself support significant dTMP incorporation; cf., row ii), each
inhibitor reduced oligo(dT) synthesis by approximately 90% (row
iii), suggesting inhibitor-induced sequestration of the enzyme by
the natural template:primer. Supporting this suggestion was the
observation that inhibitor/DNA-dependent suppression of
oligo(dT) synthesis was prevented by a high concentration of the
analogous dNTP; dGTP specifically antagonized the effect of
BuPdGTP (row iv) and dATP specifically antagonized that of
BuAdATP (row v). Additional support for the operation of the
formal sequestration mechanism was obtained from examination
of the effect ofBuPdGTP on poly(dA)-driven oligo(dT) synthesis
in the presence of the complementary homopolymeric
template:primer, poly(dC):oligo(dG). Poly(dC):oligo(dG)-
dependent inhibition (row vi) was prevented by dGTP (row vii),
and this inhibition occurred only when the complementary
poly(dC) was annealed to oligo(dG) to provide the specific
primer:template structure required for sequestration (cf., Fig. 2,
right panel). Neither poly(dC) alone (row viii) nor oligo(dG) alone
(row ix) supported the BuPdGTP-induced inhibition of oligo(dT)
synthesis.
Resistance ofBuPdGTP to polymerization: a property of pol
a not characteristic of the membership of the alpha-like DNA
polymerase family
Mammalian pol a is the structural paradigm for the alpha-like
family of viral and eukaryotic DNA polymerases-a family which
displays significant a-like primary sequence (3, 15-17). Not
surprisingly, several members of this family display a high level
of sensitivity to BuPdGTP comparable to that of pol ca. Among
the most sensitive enzymes in this family is pol T4, the
replication-specific DNA polymerase-exonuclease encoded by
coliphage T4 (15); pol T4 is inhibited by BuPdGTP with Ki in
the nanomolar range (3).
To determine whether BuPdGTP-induced inhibition of pol T4
also occurred in the absence of polymerization, we executed
primer-extension experiments like those described for pol a.
These experiments are summarized in the bottom panel of Fig.
1. Lane F displays an incubation mixture containing all 4 dNTPs;
the broad array of product lengths reflects the contention of the
respective polymerase and exonuclease activities of pol T4; the
products ranged in size from n-9 to the expected full length
product, n + 12. Lane E represents the product of incubation
dGTP alone, and despite extensive exonuclease action, it clearly
depicts a species expected for a primer extended by one dGMP
residue. Replacementof dGTP by BuPdGTP at concentrations
of 10, 100 and 1000 nanomolar (lanes B-D, respectively) clearly
generated a product with a mobility expected for primer extended
by one BuPdGMP residue.
DISCUSSION
The goal of this work was to characterize the precise molecular
mechanism of action of the dNTP form of the N2-substituted
purine inhibitor prototype which we developed as pol cx-specific
agents (1,2). The work had three specific objectives-two major
and one minor. The first was to determine whether the
BuPdNTPs, unlike the corresponding, non-polymerizable base
forms, are substrates for pol a, and the second was to determine
if BuPdNTP-induced pol a inhibition resulted from the
sequestration of the polymerase to DNA. The BuPdNTPs, indeed,
inhibited pol ae by sequestering it to the appropriate template
pyrimidine (Table II), and, based on the model behavior of
BuPdGTP, the dNTP structural format did not result in the
polymerization of the dNMP moiety to an eligible primer
terminus (cf. Fig. 1).
The third objective was to examine the generality of the pol
ca-specific mechanism of inhibition among the BuPdGTP-sensitive
members of the structurally similar alpha family (16, 17). Using
pol T4 as the model enzyme, we have demonstrated that rejection
of a BuPdNTP as a polymerizable substrate is not characteristic
of the entire BuPdNTP-sensitive alpha enzyme family. Indeed,
we show that the substrate potential of BuPdNTPs and the
inhibitory potential of BuPdNMP-terminated primers must be
carefully considered in assessing the basis for the BuPdNTP
sensitivity of a given enzyme-particularly when BuPdNTP
sensitivity is to be exploited as a means of categorizing a given
DNA polymerase and characterizing the basic structure of its
dNTP binding site.
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